Rep. David Taylor Sells Off Shares of Eli Lilly and Company (NYSE:LLY)

Key Points

• Rep. David Taylor disclosed selling $1,001–$15,000 of Eli Lilly shares on November 3 from an account linked to his trust and 401(k), according to a November 12 filing.
• Eli Lilly reported quarterly EPS of $7.48, beating the $5.71 consensus, while revenue of $24.40 billion exceeded estimates and rose 38.6% year over year.
• Analyst sentiment was broadly positive: the stock had a “Moderate Buy” consensus rating and an average price target of $1,416.64.

Representative David Taylor (Republican-Ohio) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on November 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on November 3rd. The trade occurred in the Representative's "DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) - DAVE" account.

Representative David Taylor also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Home Depot NYSE: HD on 11/5/2026.
• Sold $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 11/5/2026.
• Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 11/5/2026.
• Purchased $1,001 - $15,000 in shares of Lam Research NASDAQ: LRCX on 11/5/2026.
• Purchased $1,001 - $15,000 in shares of Eaton NYSE: ETN on 11/3/2026.
• Sold $1,001 - $15,000 in shares of Kroger NYSE: KR on 11/3/2026.
• Purchased $1,001 - $15,000 in shares of AT&T NYSE: T on 11/3/2026.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOGL on 11/3/2026.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 11/3/2026.
• Sold $1,001 - $15,000 in shares of Amgen NASDAQ: AMGN on 11/3/2026.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,444.05 on Friday. The firm has a 50 day moving average of $1,242.25 and a 200-day moving average of $1,110.30. The company has a market cap of $1.36 trillion, a price-to-earnings ratio of 44.67, a price-to-earnings-growth ratio of 1.71 and a beta of 0.40. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. Eli Lilly and Company has a 52 week low of $850.51 and a 52 week high of $1,460.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.71 by $1.77. The company had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. Eli Lilly and Company's quarterly revenue was up 38.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $7.02 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 35.70 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company's dividend payout ratio (DPR) is 22.46%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the business's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the transaction, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. This represents a 54.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on LLY shares. Cantor Fitzgerald raised their target price on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the company an "overweight" rating in a research note on Monday, November 2nd. BMO Capital Markets reaffirmed an "outperform" rating and set a $1,650.00 price target on shares of Eli Lilly and Company in a research note on Friday, October 30th. Truist Financial reiterated a "buy" rating and issued a $1,612.00 price target (up from $1,376.00) on shares of Eli Lilly and Company in a report on Friday, October 30th. Royal Bank Of Canada raised their price objective on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an "outperform" rating in a research note on Friday, October 30th. Finally, Leerink Partners raised their price objective on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an "outperform" rating in a research note on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,416.64.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its holdings in shares of Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock worth $81,009,981,000 after purchasing an additional 1,046,558 shares during the period. State Street Corp lifted its stake in Eli Lilly and Company by 1.7% in the third quarter. State Street Corp now owns 36,848,565 shares of the company's stock valued at $42,636,738,000 after purchasing an additional 632,811 shares during the last quarter. Bank of America Corp DE bought a new position in Eli Lilly and Company during the second quarter valued at $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Eli Lilly and Company by 1.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock valued at $8,647,153,000 after purchasing an additional 137,364 shares during the period. Finally, Jennison Associates LLC increased its position in Eli Lilly and Company by 7.9% in the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock worth $6,550,587,000 after buying an additional 400,538 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Recent Eli Lilly and Company Headlines

These are some of the LLY headlines that stood out recently:

• Positive Sentiment: China approved Lilly’s oral weight-loss drug orforglipron, marketed as Foundayo. As the first GLP-1 weight-loss pill approved in China, it gives Lilly an early foothold in a large market and could broaden access beyond injectable treatments; competition from other drugmakers remains a factor. Reuters: China approves Eli Lilly's weight loss pill orforglipron
• Positive Sentiment: Hims & Hers will offer Lilly’s FDA-approved Zepbound and Foundayo, potentially extending patient reach through another care platform. Separately, exchange-traded funds were reported to have added to their Lilly holdings, signaling investor demand. Hims partners with Lilly to offer weight-loss drugs
• Negative Sentiment: China Merchants Securities downgraded Lilly from “buy” to “hold,” providing a cautionary view amid the positive product and capacity news. China Merchants Securities stock recommendations

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio's 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Taylor (Republican Party) ran for election to the U.S. House to represent Ohio's 2nd Congressional District. He won in the general election on November 5, 2024. David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor's career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.